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Background: The epithelial cell adhesion molecule (EpCAM) is overexpressed on most carcinomas. Dependent on the tumour
type, its overexpression is either associated with improved or worse patient survival. For ovarian cancer, however, the role of
EpCAM remains unclear.
Methods: Cell survival of ovarian cancer cell lines was studied after induction or repression of endogenous EpCAM expression
using siRNA/cDNA or artificial transcription factors (ATF) consisting of engineered zinc-fingers fused to either a transcriptional
activator or repressor domain.
Results: Two ATFs were selected as the most potent down- and upregulator, showing at least a two-fold alteration of EpCAM
protein expression compared with control. Downregulation of EpCAM expression resulted in growth inhibition in breast cancer,
but showed no effect on cell growth in ovarian cancer. Induction or further upregulation of EpCAM expression decreased ovarian
cancer cell survival.
Conclusion: The bidirectional ATF-based approach is uniquely suited to study cell-type-specific biological effects of EpCAM
expression. Using this approach, the oncogenic function of EpCAM in breast cancer was confirmed. Despite its value as a
diagnostic marker and for immunotherapy, EpCAM does not seem to represent a therapeutic target for gene expression silencing
in ovarian cancer.
The epithelial cell adhesion molecule (EpCAM; CD326) is a
transmembrane glycoprotein, overexpressed on the vast majority
of carcinomas compared with healthy epithelium (Went et al,
2004). Epithelial cell adhesion molecule is used as a diagnostic
marker, has prognostic value for some tumours (Went et al, 2008)
and even serves as a therapeutic target in antibody-based therapies
(Baeuerle and Gires, 2007). Recently, EpCAM has been identified
as a marker for cancer-initiating stem cells (Visvader and
Lindeman, 2008) and was shown to be involved in the Wnt-
signaling pathway (Maetzel et al, 2009). Upon intramembrane
proteolysis of EpCAM, the intracellular domain functions with b-
catenin as part of a transcriptional complex inducing c-myc and
cyclin A/E expression. In breast cancer, high EpCAM expression is
associated with poor prognosis, (Spizzo et al, 2004), which is
consistent with the finding that induction of EpCAM in the
EpCAM-negative breast cancer cell line Hs578T showed increased
proliferation compared with the empty vector control (Gostner
et al, 2011). In addition, RNAi-based silencing of EpCAM
expression in breast cancer cell lines reduced the oncogenic
potential of the treated cells (Osta et al, 2004) and EpCAM
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expression rescued by cDNA constructs increased cell invasion
(Sankpal et al, 2011).
Despite this oncogenic function of EpCAM in breast carcino-
genesis, for several tumour types the biological role of EpCAM is
far from clear (van der Gun et al, 2010). Clinical observations in
ovarian cancer suggest that for this tumour type EpCAM
overexpression correlates with decreased overall survival, especially
in patients with FIGO stage III/IV (Spizzo et al, 2006), although
this could not be confirmed by independent studies (Kim et al,
2003; Heinzelmann-Schwarz et al, 2004). In addition, EpCAM has
been described as a marker of human ovarian cancer stem/
progenitor cells (Meirelles et al, 2012) and introduction of human
EpCAM cDNA in EpCAM-negative mouse ovarian stem-like
tumour cells enhanced the tumour-initiating ability (Motohara
et al, 2011). Although these studies are far from definitive, they do
suggest that downregulation of endogenous EpCAM expression
might decrease the oncogenic potential in ovarian cancer.
To our knowledge, so far no data exist on EpCAM expression
modulation in human ovarian cell culture systems in contrast to
breast and many other tumour types. To investigate the functional
role of EpCAM, a method to modulate bidirectionally endogenous
expression levels would provide biologically relevant insights. To
this end, artificial transcription factors (ATFs) can be constructed
by fusing a gene-specific DNA-binding domain to transcriptional
modulators (Uil et al, 2003). DNA-binding domains often used are
engineered six zinc-fingers targeting an 18-base-pair unique
sequence, thereby, enabling specific targeting of virtually any gene
(Sera, 2009). Artificial transcription factors are appealing because
they allow for both up- (Beltran and Blancafort, 2011) and
downregulation (Stolzenburg et al, 2012) of gene expression, by
fusing an activator or repressor to the zinc-fingers. Furthermore,
compared with siRNA approaches where many mRNA copies have
to be targeted, only two gene copies need to be targeted by ATFs.
In addition, compared with gene delivery approaches, which often
involve the expression of only one cDNA variant, ATFs can induce
all splice variants in their natural ratios. Importantly, using this
approach, epigenetic effector domains can be targeted to the gene
of interest to induce mitotically stable gene expression modulation
(De Groote et al, 2012). In this study, bidirectional endogenous
EpCAM modulation by ATFs was exploited to investigate the
biological role of EpCAM overexpression in ovarian cancer.
MATERIALS AND METHODS
Cell culture. HEK293T cells, and the cancer cell lines HeLa
(cervix), MCF7, MDA-MB231, SKBR3 (breast) and OVCAR3,
CaOV3, SKOV3 and A2780 (ovarian) were cultured in DMEM
(BioWhittaker, Walkersville, MD, USA) with 50 mgml 1 genta-
micin sulphate, 2mM L-glutamine and 10% FBS.
ATF retroviral transduction. Epithelial cell adhesion molecule
targeting zinc-finger proteins (ZFPs): one 3-finger (3F-ZFA) and
two 6-fingers (referred to as ZFA and ZFB) (Gommans et al, 2007)
were subcloned into the retroviral vector pMX-IRES-GFP (pMX)
(Beltran and Blancafort, 2011) containing the activator VP64
(a tetrameric repeat of herpes simplex VP16) (Beltran and
Blancafort, 2011) or the repressor SKD (Kruppel-associated box)
(Stolzenburg et al, 2012). Retroviral particles were produced by co-
transfection of pMX with the VSV envelope protein (pMD2.G) and
the gag/pol proteins (pMDLg/pRRE) into HEK293T cells using
CaPO4. After 2 and 3 days, the viral supernatant was used to
transduce the host cell lines in the presence of 5 mgml 1 polybrene
(Sigma, St Louis, MO, USA). Transduction was optimized by, for
example, diminishing toxicity to 293 producer cells (lowering the
amount of plasmids in the transfection) and by varying the number
of host cells seeded. Cells were harvested for analysis, 4 days after
the first transduction. As the IRES-GFP present in the pMX vector
showed a relative low GFP signal (Beerli et al, 2000), co-
transduction with a strong GFP reporter was used to monitor
toxicity by downregulation of EpCAM expression in SKBR3 cells.
siRNA or cDNA transfection. siRNA-EpCAM 750 ng (sense, 50-
GGAGAUCACAACGCGUUAUUU and antisense, 50-AUAA
CGCGUUGUGAUCUCCUU) or irrelevant-siRNA (irr-siRNA)
(1022076; Qiagen, Venlo, Netherlands) or plasmid DNA (gener-
ously provided by Giepmans, UMCG and Cirulli (Washington,
DC, USA)) (Schnell et al, 2012) was complexed in 200 ml HBS with
20 ml SAINT-2:DOPE (SD; 0.75mM) (Synvolux, Groningen,
Netherlands) and pipetted onto the SKOV3 or A2780 cells.
Gene expression analysis. Q-RT-PCR was performed (ABIPrism
7900HT, Applied Biosystems, Nieuwekerk, Netherlands) for
EpCAM (Hs00158980_m1, Applied Biosystems) and GAPDH
(F, 50-CCACATCGCTCAGACACCAT-30; R, 50-GCGCCCAATA
CGACCAAAT-30; probe: 50-CGTTGACTCCGACCTTCACCTT
CCC-30; (Eurogentec, Maastricht, Netherlands)) in triplicate.
Results are shown as relative expression compared with GAPDH
levels, using DCt method (pMX was set at 1). Epithelial
cell adhesion molecule protein was detected by APC-CD326
(BioLegend, Uithoorn, Netherlands). The mean fluorescence
intensity (pMX was set at 100%) was measured on a Calibur flow
cytometer (Beckton Dickenson Biosciences, San Jose, CA, USA).
Cell growth assays. Transduction was carried out directly in 96-
well plates and cell viability MTT assay (M2128; Sigma) was
performed at days 4, 5 and 6 after transduction, or transductions
were carried out in 6-well plates and host cells were harvested at
day 4 after transduction, replated at equal numbers in 96-well
plates and MTT assay was performed for the four following days.
After 3.5 h of MTT incubation, plates were centrifuged, the
medium was aspirated and 200 ml DMSO was added. Absorption
was measured at 560 nm (Varioskan microplate spectrophot-
ometer; Thermo Scientific, Breda, Netherlands), and background
was subtracted at 670 nm. To estimate cell numbers after
treatment, cells were fixed and stained with methanol/acetic acid/
water mixture (50%, 20% and 30% respectively), containing 0.01%
Coomassie brilliant blue (Sigma) visualizing protein content. In
addition, clonogenic survival assay was performed by replating
cells in 6-well plates at day 4 after transduction, colonies were
allowed to grow for 15–21 days and visualized as described above.
RESULTS
Bidirectional modulation of EpCAM expression. To identify
which ATF could effectively modulate EpCAM expression, ATFs
were screened in a panel of carcinoma cell lines by using sub-
optimal retroviral transductions (Supplementary Figure 1).
This screening approach identified ZFASKD and ZFBVP64 as the
most potent down- and upregulators of EpCAM expression,
respectively. ZFBVP64 showed no effect on Her2neu and ICAM
expression (data not shown), whereas an ATF designed to target
the Her2neu gene (Beerli et al, 2000) effectively up- (E2C-VP64) or
downregulated (E2C-SKD) Her2neu expression in HeLa, but
showed no effect on EpCAM expression (Supplementary
Figure 1D and E).
Functional validation of downregulation of EpCAM expression
by ATFs. Downregulation of EpCAM expression by RNAi in
breast cancer reduces the oncogenic potential (Osta et al, 2004;
Sankpal et al, 2011). Therefore, we validated that downregulation
of EpCAM expression by ATFs in breast cancer also induced
similar phenotypic alterations. SKBR3 cells were co-transduced
with ZFASKD and a strong GFP reporter vector to track the
percentage of transduced cells. As negative controls, ZFAVP64 and
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pMX (empty vector control) were used. At 4 days after
transduction, all conditions displayed approximately 50% GFP-
positive cells (Figure 1A). Compared with pMX, ZFASKD-
transduced cells showed a 2.3-fold reduction in EpCAM protein
expression, whereas the EpCAM expression of ZFAVP64- and
pMX-transduced cells was similar (Figure 1B). After normalizing
for cell numbers and subculturing, ZFASKD-transduced cells
proliferated less rapidly than the cells transduced with pMX or
ZFAVP64, requiring less cell passaging. Indeed, after 17 days of
subculturing, the ZFASKD-transduced cell population only con-
tained 20% GFP-positive cells, whereas the cells transduced with
pMX or ZFAVP64 still displayed 50% GFP-positive cells
(Figure 1A). This finding indicates that the unaffected EpCAM-
expressing cell population overgrew the ZFASKD-expressing
SKBR3 population, which is also reflected in the restored EpCAM
expression of the cell population (Figure 1B). The reduced
proliferation displayed by the reduced EpCAM-expressing breast
cancer cells was also confirmed by a colony-forming assay. The
number of colonies formed by SKBR3 cells expressing ZFASKD
was clearly less than the number of colonies formed by the cells
transduced with pMX and ZFAVP64 (Figure 1C).
Biological role of EpCAM expression in ovarian cancer. As the
biological role of EpCAM in ovarian cancer is unclear (van der
Gun et al, 2010), we set out to provide such insights by
bidirectionally modulating EpCAM expression in intermediate
EpCAM-expressing ovarian cancer cells (SKOV3). The transduc-
tion protocol was improved to yield at least 80% of GFP-positive
ovarian cancer cells expressing ZFASKD or ZFBVP64. Compared
with cells transduced with pMX, ZFASKD-expressing cells
displayed a two-fold reduction of EpCAM expression on RNA
(0.5±0.1; Po0.001) and on protein level (41±2% expression left;
Po0.001) (Figure 2A). The ZFAVP64- and ZFBVP64-transduced
cells demonstrated increased EpCAM protein expression
(213±22%; Po0.01 and 340±33%; Po0.001), respectively). Cells
transduced to express ZFBNoED (NoED¼ no effector domain)
without an effector domain also exhibited upregulation (178±4%;
Po0.001), which was not observed for ZFANoED (Figure 2A).
Because ZFASKD and ZFBVP64 modulated EpCAM expression
most effectively, these ATFs were further selected to investigate the
phenotypical change due to EpCAM gene downregulation vs
overexpression. Unexpectedly, at day 4 after transduction, not
ZFASKD- but ZFBVP64-transduced cells showed less cell survival
as shown by staining (Figure 2B, left inset) compared with the cells
transduced with pMX (empty vector control). Cells transduced
with pMX, ZFBNoED or ZFASKD showed comparable survival.
This observation was confirmed by cell viability MTT assays
performed on days 4, 5 and 6 after transduction: less cell survival
was observed after transduction with ZFBVP64, whereas pMX,
ZFASKD and ZFBNoED displayed the same cell growth rate
(Figure 2B, left). Also, after harvesting the different transduced cell
populations at day 4 after transduction, MTT assays performed on
the equal numbers of replated cells showed exactly the same trend:
ZFBVP64-transduced cells did poorly attach to the wells and were
hardly capable to proliferate, whereas ZFASKD and ZFBNoED
showed the same growth rate as pMX (Figure 2B, right).
Furthermore, enforced ectopic cDNA expression of EpCAM did
not result in growth induction of ovarian cells (Supplementary
Figure 2A). To exclude that the expression of VP64 itself was toxic
for the cells, transductions were performed with an irrelevant ZFP
fused to VP64 (ZFirrVP64), with ZFAVP64 and the controls
ZFANoED and pMX. Again, ZFBVP64-transduced cells clearly
showed less cell survival (Supplementary Figure 2B), whereas all
other constructs displayed comparable cell numbers with pMX.
siRNA-based silencing of EpCAM expression in ovarian cancer
has no effect on cell growth. The biological effect of increased
EpCAM expression was in contrast with our initial hypothesis that
reduced EpCAM expression in ovarian cancer would result in growth
inhibition. To confirm that indeed downregulation of EpCAM
expression had no effect on cell proliferation, we validated our finding
with the conventional approach of silencing EpCAM expression by
siRNA. After transfection of EpCAM-siRNA into SKOV3 cells,
EpCAM RNA expression was almost completely silenced and protein
expression was reduced by 95% (Figure 3A), whereas irr-siRNA had
no effect on EpCAM expression. Despite the efficient downregulation
of EpCAM, again equal growth rates were observed for EpCAM-
siRNA- and irr-siRNA-treated cells (Figure 3B).
Increased EpCAM expression levels correlated with cell growth
inhibition. To investigate whether the growth inhibition asso-
ciated with induced EpCAM overexpression could be phenotypi-
cally rescued, ZFBVP64-transduced SKOV3 cells were transfected
with EpCAM-siRNA. At day 1 after siRNA transfection, the
ZFBVP64-induced 3.3-fold upregulation of EpCAM protein
expression was reduced by the combination with siRNA to only
1.8-fold upregulation compared with ZFBVP64 and irr-siRNA
treatment (Figure 4A). At day 3, only 16% EpCAM expression
compared with mock-treated cells was left. Despite the efficient
downregulation of EpCAM expression at day 3, this reduction
could not rescue the growth inhibition caused by the initial ATF-
induced EpCAM overexpression (Figure 4B).
As downregulation of EpCAM expression after upregulation of
EpCAM expression had no effect on cell survival, we investigated
whether we could prevent the induced upregulation by simulta-
neous downregulation of EpCAM expression. SKOV3 cells were
























































Figure 1. Downregulation of EpCAM expression by ATFs inhibits cell
growth in breast cancer cells. SKBR3 cells were transduced to express
the indicated ATFs. At days 4 and 21 after transduction, the percentage
of GFP-positive (A) and the relative EpCAM protein expression (B; pMX
set at 100) was measured by flow cytometry. (C) Clonogenic survival
assay: 4 days after transduction cells were equally replated in 6-well
plates and allowed to grow colonies for 16 days when surviving
colonies were stained. MFI, mean fluorescence intensity.
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mixed with pMX and or ZFASKD. Although the pMX–ATF
mixtures induced a gradual decrease of EpCAM upregulation
(Figure 4C, inset), the lowest induced upregulation was still 1.9-
fold and only a slight recovery from growth inhibition was
observed (Figure 4C). Subsequent induction of different levels of
endogenous EpCAM expression (e.g. by titration of pMX-6-ZF-B-
VP64 with ZFASKD) confirmed that exceeding a threshold of
EpCAM expression resulted in irreversible growth inhibition
(Supplementary Figure 3).
Induction of EpCAM expression in EpCAM-negative ovarian
cancer cell line. To further validate our unexpected finding that
up-regulation of EpCAM expression resulted in growth inhibition
in ovarian cancer, we investigated the phenotypical changes due to
induction of EpCAM in the EpCAM-negative ovarian cancer cell
line A2780. Indeed, ZFBVP64-transduced A2780 cells clearly
displayed a lower number of surviving cells than pMX-transduced
cells and again growth inhibition was observed (Figure 5A).
Transfection of an EpCAM cDNA-expressing plasmid also induced
growth inhibition (Supplementary Figure 2). When surviving
infected cells were harvested at day 4 and replated at equal
densities, the same growth rate was obtained for cells transduced
with pMX, ZFBNoED or ZFBVP64 (Figure 5B). The difference in
growth capacity of direct treated cells (Figure 5A) compared with
the replated surviving cell population (Figure 5B) can be explained
by the cytotoxic effect of the induced EpCAM expression. At day 4,





















































































































































Figure 2. Phenotypical effect of up- and downregulation of EpCAM expression in ovarian cancer. SKOV3 cells were transduced to express the
indicated ATFs in 6- and 96-well plates. (A) At day 4 after transduction, cells were harvested and analysed for EpCAM mRNA (left; pMX set at 1)
and protein (right; pMX set at 100) expression (mean±s.e.m., nX5; t-test **Po0.01, ***Po0.001). (B) At day 4 after transduction, cells were fixed,
stained (inset) and 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay was performed at days 4, 5 and 6 after transduction
(left) or cells were replated at equal cell numbers and MTT assay was performed for the four following days (right). GAPDH, glyceraldehyde 3-



































































Figure 3. SiRNA-based silencing of EpCAM expression in ovarian cancer has no effect on cell growth. SKOV3 cells were transfected with
irr-siRNA or EpCAM-siRNA. At days 1 to 3 after transfection, EpCAM mRNA, protein expression (A) and 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT) assay (B) were analysed (SD set at 100¼delivery agent). MFI, mean fluorescence intensity; OD, optical density.
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only 35±3% of the A2780 cells was still GFP-positive compared
with 85±2% and 80±10% for ZFBNoED and ZFASKD, respec-
tively. In contrast, ZFBVP64-transduced SKOV3 cells displayed at
day 4 after transduction 84±5% GFP-positive cells compared with
96±1% and 93±6% for ZFBNoED and ZFASKD, respectively.
DISCUSSION
Dependent on the tumour type, EpCAM overexpression has been
associated with either decreased or increased overall survival of
patients (van der Gun et al, 2010). Although this dual role is also
reflected by EpCAM modulation studies, for human ovarian cancer
no such siRNA/cDNA studies have been reported and the
biological role of EpCAM here remains unclear. This study is the
first to report that downregulation of EpCAM expression in
human ovarian cancer does not decrease growth rate, not when
using a repressive ATF nor after siRNA-mediated downregulation.
Importantly, ATF-induced EpCAM downregulation did result in
cell growth inhibition for breast cancer, confirming previous RNA
interference studies for this carcinoma type (Osta et al, 2004;
Sankpal et al, 2011).
As our findings suggest the absence of an oncogenic role for
EpCAM in human ovarian cancer, we set out to induce or further
upregulate EpCAM expression in EpCAM-negative or low
expressing ovarian cancer cells. As has also been reported for
renal cell (Klatte et al, 2009) and thyroid carcinomas (Ralhan et al,
2010), we observed an inhibition in cell growth by inducing
EpCAM expression. As ablation of p53 expression has been
associated with an increase in EpCAM expression (Sankpal et al,
2009), the commonly observed EpCAM overexpression in ovarian
cancer might be a consequence of p53 dysfunction, ubiquitously
observed for ovarian cancers (Ahmed et al, 2010). Indeed, although
EpCAM expression enhanced the tumour-initiating ability of
ovarian stem-like cells, a significant outgrowth of tumour mass was
only observed for EpCAM-positive cells when p53 was down-
regulated (Motohara et al, 2011). In addition, a growth-promoting
role of EpCAM via Wnt signalling, an important pathway in
cancers, might not be of general importance in the development of
cancer. Whereas EpCAM overexpression in MDA-MB231 could
activate Wnt signalling, this was not observed in Hs578T (Gostner
et al, 2011). Alternatively, the high EpCAM expression commonly
observed on ovarian cancer cells could be explained by a recent
postulation stating that high-grade serous ovarian cancer arises
from the fallopian tube instead of the ovary (Reitsma et al, 2012).
The relative increase of EpCAM protein expression in ovarian
cancer (2.8 on a scale of 0–3) compared with healthy fallopian tube
epithelium (1.8) is only 1.5-fold, whereas the increase of EpCAM




































































































Figure 4. Increased EpCAM expression levels correlate with cell growth inhibition. SKOV3 cells were transduced with pMX and ZFBVP64.
At day 4 after transduction, cells were equally replated. Next day, siRNA transfection was performed, and subsequently at 3 days, EpCAM protein
(A) and 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay (B) were analysed. (C) SKOV3 cells were transduced with a
constant amount of ZFBVP64 virus supernatant mixed with pMX and/or ZFASKD. At day 4 after transduction, EpCAM protein expression was
measured (inset) and transduced cells were replated at equal cell numbers, and MTT assay was performed for the four following days.












































Figure 5. Induction of EpCAM expression in EpCAM-negative ovarian cancer cell line. A2780 cells were transduced to express the indicated ATFs
in 6- and 96-wellsplates. (A) At day 4, transduced cells were fixed and stained, or 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT assay was performed at days 4, 5 and 6 after transduction. (B) Transduced cells were harvested at day 4 after transduction, replated at equal
cell numbers in 96-well plates and MTT assay was performed for the four following days. OD, optical density.
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protein expression compared with ovarian surface epithelium (0.2)
is 14-fold (Emmanuel et al, 2011).
As EpCAM is frequently overexpressed in ovarian cancer, anti-
EpCAM antibodies are successfully exploited to recruit immune
effector cells, resulting in ovarian cancer cell lysis (Richter et al,
2010). Despite this important role of EpCAM in ovarian cancer
therapy, we show here that inhibition of EpCAM expression does
not offer a promising therapeutic approach for ovarian cancer.
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